Elicit: Impact of Continuous Glucose Monitors on Diabetes Complications
Impact of Continuous Glucose Monitors on Diabetes Complications
What is the impact of continuous glucose monitors on reducing long-term diabetes complications such as cardiovascular disease, neuropathy, and kidney disease?
Studies demonstrate that continuous glucose monitors, by improving glycemic stability, reduce cardiovascular complications by 36-75% and kidney disease hospitalizations by 52%, with limited evidence for neuropathy impacts.
Abstract
Continuous glucose monitors (CGMs) improve glycemic control by reducing HbA1c levels (by 0.2%–0.76%), increasing time in range, and lowering hypoglycemia exposure. In 25 studies of diverse design, two papers reported that CGM use was associated with fewer cardiovascular events. One reported relative risk reductions of 52% for stroke (RR 0.48), 36% for myocardial infarction (RR 0.64), 41% for atrial fibrillation (RR 0.59), and 75% for heart failure (RR 0.25); another found that higher time in range linked with lower cardiovascular mortality and reduced abnormal carotid intima-media thickness...
Methods
We analyzed 25 sources from an initial pool of 500, using 7 screening criteria. Each paper was reviewed for 5 key aspects that mattered most to the research question.
Paper search
Using your research question “What is the impact of continuous glucose monitors on reducing long-term diabetes complications such as cardiovascular disease, neuropathy, and kidney disease?”, we searched across over 126 million academic papers from the Semantic Scholar corpus. We retrieved the 500 papers most relevant to the query.
Screening
We screened in sources based on their abstracts that met these criteria:
- Population Age: Does the study focus exclusively on adult participants (≥18 years) with type 1 or type 2 diabetes?
- Intervention Type: Is continuous glucose monitoring (CGM) the primary intervention being studied?
- Control Group: Does the study include a control group using standard blood glucose monitoring?
- Study Duration: Is the study duration at least 12 months?
- Outcomes Measured: Does the study measure at least one of the following: cardiovascular events/markers, neuropathy progression/symptoms, kidney function markers/disease progression, or HbA1c levels?
- Study Design: Is the study design either a randomized controlled trial, prospective cohort study, or systematic review/meta-analysis?
- Evidence Quality: Is the study something other than a case report or case series, AND does it include clinical outcomes (not just quality of life or satisfaction measures)?
Data extraction
We asked a large language model to extract each data column from each paper.
Results
Characteristics of Included Studies
| Study | Study Design | Population Size | Duration | Primary Outcomes Measured |
|---|---|---|---|---|
| Anderson et al., 2011 | Retrospective cohort study | 77 | Long-term (≥3 months), Short-term (<3 months) | Hemoglobin A1c (HbA1c) changes, Hypoglycemia exposure |
| Cho et al., 2023 | Prospective observational cohort study | 539 | 1 year | HbA1c changes, Time in glycemic range, Hypoglycemia exposure |
| Dinneen et al., 2009 | Randomized Controlled Trial (RCT) - Parallel group | 404 | 18 months | HbA1c changes |
| Eeg-Olofsson et al., 2024 | Retrospective cohort study | 11,822 | No mention found | HbA1c changes, Hypoglycemia exposure, Long-term complications (cardiovascular, kidney disease) |
| Idris, 2023 | Observational retrospective study | 20,721 | 12 months | HbA1c changes, Hypoglycemia exposure, Hyperglycemia exposure, All-cause hospitalization |
| ... |
Among the included studies, we found a mix of study designs and characteristics:
- Study Design:
- Retrospective cohort studies appeared to be the most common (7 studies)
- Meta-analyses and systematic reviews (5 studies)
- Randomized Controlled Trials (RCTs) (7 studies total, with 4 parallel and 3 crossover designs)
- Population Size:
- 11 studies had between 100-1000 participants
- 7 large-scale studies with over 10,000 participants
- 4 studies with 1000-10000 participants
- 3 studies with fewer than 100 participants
Effects of Continuous Glucose Monitoring (CGM) on Diabetes Complications
Cardiovascular Outcomes
Study
| Outcome Type | Effect Size | Follow-up Duration | Key Findings |
|---|---|---|---|
| Eeg-Olofsson et al., 2024 | Hospitalization for cardiovascular events | Relative risk reductions | No mention found |
| ... |
Neurological Complications
....
Renal Outcomes
....
Relationship Between Glycemic Variability and Complications
....
Implementation Factors
Duration of Continuous Glucose Monitoring (CGM) Use
....
Technology Type Impact
....
References
- M. Yapanis, S. James, M. Craig, David N. O’Neal, E. Ekinci (2022). Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring. Journal of Clinical Endocrinology and Metabolism
- R. Vigersky et al. (2011). Short- and Long-Term Effects of Real-Time Continuous Glucose Monitoring in Patients With Type 2 Diabetes. Diabetes Care
- R. Janapala et al. (2019). Continuous Glucose Monitoring Versus Self-monitoring of Blood Glucose in Type 2 Diabetes Mellitus: A Systematic Review with Meta-analysis. Cureus